Burning Rock Biotech Ltd
BNR · XNASCIK 1792267fmd_0AJACEC8NS7MW5MBKAK5EGZF24Services · Services-Medical LaboratoriesTemplate: Standard
Coverage: Jan 01, 2018 to Dec 31, 2025, 10 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total interest income | 1 | 11 | 6 | 3 | 9 | 18 | 12 | 8 |
| Total revenues | 209 | 382 | 430 | 508 | 563 | 537 | 516 | 540 |
| Cost of revenue | 74 | 108 | 116 | 144 | 183 | 174 | 153 | 137 |
| Net interest income | (17) | 2 | (1) | (2) | 0 | 0 | 0 | (0) |
| Gross profit | 135 | 273 | 314 | 364 | 380 | 363 | 362 | 403 |
| Realized investment gains (losses) | – | – | – | – | 0 | 0 | 5 | – |
| Research and development | 105 | 157 | 264 | 368 | 422 | 347 | 232 | 166 |
| Selling, general and administrative | 191 | 285 | 462 | 793 | 939 | 686 | 453 | 291 |
| Operating income | (161) | (169) | (412) | (797) | (980) | (669) | (358) | (55) |
| Interest expense | 18 | 9 | 1 | 2 | – | – | – | – |
| Income before taxes | (177) | (169) | (407) | (796) | (969) | (651) | (341) | (54) |
| Income tax expense | 0 | 0 | 0 | 1 | 2 | 2 | 6 | 2 |
| Net income from continuing operations | (177) | (169) | (407) | (797) | (971) | (654) | (347) | (55) |
| Net income | (177) | (169) | (407) | (797) | (971) | (654) | (347) | (55) |
| Net income to common shareholders | (232) | (334) | (472) | (797) | (971) | – | – | – |